In a 64-year-old woman with type 2 diabetes and established atherosclerotic cardiovascular disease who needs additional glucose‑lowering therapy, which medication class offers proven cardiovascular and renal protection?

SGLT2 Inhibitors Are the Medication Class of Choice

For a 64-year-old woman with type 2 diabetes and established atherosclerotic cardiovascular disease requiring additional glucose-lowering therapy, SGLT2 inhibitors (empagliflozin, canagliflozin, or dapagliflozin) are the definitive choice, offering proven cardiovascular and renal protection with strong guideline support. 1, 2

Why SGLT2 Inhibitors Are Superior

The evidence is unequivocal: SGLT2 inhibitors provide dual cardiovascular and renal protection specifically in this patient population. Multiple high-quality guidelines converge on this recommendation:

• Strong Recommendation (Grade 1A): SGLT2 inhibitors reduce the risk of heart failure hospitalization and death in patients with type 2 diabetes and atherosclerotic cardiovascular disease 1
• Renal Protection: The DAPA-CKD trial demonstrated a 44% reduction in the composite outcome of sustained eGFR decline ≥50%, end-stage kidney disease, or death from renal/CV causes (HR 0.56,95% CI 0.45-0.68) 1
• Mortality Benefit: All-cause mortality was reduced by 31% (HR 0.69,95% CI 0.53-0.88) 1

Specific Agent Selection

Choose from three agents with proven cardiovascular outcomes:

• Empagliflozin: 10-25 mg daily
• Canagliflozin: 100-300 mg daily
• Dapagliflozin: 10 mg daily

All three have demonstrated cardiovascular benefit in this population 1, 3. No dose titration is required—start at the therapeutic dose 4.

eGFR Thresholds for Initiation

Initiate SGLT2 inhibitors if eGFR ≥20 mL/min/1.73 m² 5, 6. This represents an important update from older thresholds:

• The 2022 KDIGO guideline lowered the initiation threshold from ≥30 to ≥20 mL/min/1.73 m² based on new trial data 6
• Continue therapy even if eGFR falls below 20 mL/min/1.73 m² until dialysis is initiated 5, 6
• Cardiovascular and renal benefits persist at lower eGFR levels, independent of glucose-lowering effects 5

GLP-1 Receptor Agonists: The Alternative

If SGLT2 inhibitors cannot be used, GLP-1 receptor agonists (liraglutide, semaglutide, or dulaglutide) are the second-line choice for cardiovascular protection 5, 3, 2. However, they provide:

• Cardiovascular benefit: Reduction in MACE (myocardial infarction, stroke, CV death) 5, 3
• Modest renal benefit: Primarily through albuminuria reduction and slowing eGFR decline, but without dedicated renal outcome trials 5

The key distinction: SGLT2 inhibitors offer superior renal protection with dedicated kidney outcome trials, while GLP-1 RAs excel at MACE reduction 5.

Combined Therapy Consideration

For maximal cardiovascular and renal protection, consider combining an SGLT2 inhibitor with a GLP-1 RA 2. The 2025 ADA Standards recommend this combination in patients with established ASCVD or multiple risk factors for additive reduction of adverse cardiovascular and kidney events 2.

Critical Safety Considerations

Expected eGFR Dip

• Anticipate an initial 3-5 mL/min/1.73 m² decline in eGFR within the first weeks 7
• This is hemodynamic, not nephrotoxic—kidney function typically returns to baseline and remains stable 7
• Do not discontinue therapy for this expected change 7

Genital Mycotic Infections

• Most common adverse effect (10-15% risk in women) 1
• Manage with antifungal therapy; rarely requires drug discontinuation 1

Euglycemic Diabetic Ketoacidosis

• Rare but serious complication 7
• Discontinue SGLT2 inhibitor 3-4 days before elective surgery or invasive procedures 7
• Counsel patients on sick-day management: stop during acute illness with reduced oral intake 7

Volume Depletion

• Risk increased in elderly, those on diuretics, or with low systolic blood pressure 3
• Monitor volume status, particularly at initiation 3

Amputation Risk (Canagliflozin-Specific)

• Increased risk observed with canagliflozin in CANVAS trial 3
• Use caution in patients with prior amputation, severe peripheral vascular disease, neuropathy, or diabetic foot ulcers 3
• No increased amputation risk with empagliflozin or dapagliflozin 3

Contraindications

• Type 1 diabetes 1
• Pregnancy or breastfeeding 4
• History of serious hypersensitivity reaction 3

Practical Implementation

1. Start immediately: Do not wait for metformin optimization given the patient's established ASCVD 1, 7
2. No dose adjustment needed for renal function if eGFR ≥20 mL/min/1.73 m² 5, 6
3. Reduce insulin/sulfonylurea doses if used concomitantly to prevent hypoglycemia 3
4. Monitor: Baseline and periodic eGFR, volume status, foot care in high-risk patients 3, 7

Why Not Other Agents?

• Metformin: Glucose-lowering only; no proven cardiovascular or renal protection 5
• DPP-4 inhibitors: Neutral cardiovascular effects 8
• Thiazolidinediones: Increase heart failure risk 8
• Sulfonylureas: Hypoglycemia risk without cardiovascular benefit 5